ArticleCurrent genomics2011
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.
Article in Current genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Insights on the Association between Thyroid Diseases and Colorectal Cancer.Journal of clinical medicine · 2023Review
- Is Melanoma Progression Affected by Thyroid Diseases?International journal of molecular sciences · 2022Review
- Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model.Biomedicines · 2022Article
- Papillary Thyroid Cancer Prognosis: An Evolving Field.Cancers · 2021Review
- A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.International journal of molecular sciences · 2021Review
- Synergistic Anticancer Activity ofInternational journal of molecular sciences · 2021Article
- Article
- Comprehensive Assessment ofCancers · 2020Article
- Poorly differentiated thyroid carcinoma : An underdiagnosed entity.Der Pathologe · 2020Review
- Anaplastic thyroid cancer: How far can we go?EXCLI journal · 2020Review
- [Poorly differentiated thyroid carcinoma : An underdiagnosed entity. German version].Der Pathologe · 2019Article
- Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma.Endocrinology, diabetes & metabolism case reports · 2019Article
- SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.BMC cancer · 2018Article
- Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer.Endocrine connections · 2018Article
- Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer.OncoTargets and therapy · 2018Article
- cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis.Diagnostic pathology · 2017Article
- The Chinese herbOncology letters · 2017Article
- EWSR1 rearrangement is a frequent event in papillary thyroid carcinoma and in carcinoma of the thyroid with Ewing family tumor elements (CEFTE).Virchows Archiv : an international journal of pathology · 2017Article
- Lymph Node Metastases in Papillary and Medullary Thyroid Carcinoma Are Independent of Intratumoral Lymphatic Vessel Density.European thyroid journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range from well differentiated, papillary and follicular carcinoma (PTC and FTC, respectively), usually carrying a good prognosis, to the clinically aggressive, poorly differentiated (PDTC) and undifferentiated thyroid carcinoma (UTC).It is usually accepted that PDTC and UTC occur either de novo or progress from a pre-existing well differentiated carcinoma through a multistep process of genetic and epigenetic changes that lead to clonal expansion and neoplastic development. Mutations and epigenetic alterations in PDTC and UTC are far from being totally clarified. Assuming that PDTC and UTC may derive from well differentiated thyroid carcinomas (WDTC), it is expected that some PDTC and UTC would harbour genetic alterations that are typical of PTC and FTC. This is the case for some molecular markers (BRAF and NRAS) that are present in WDTC, PDTC and UTC. Other genes, namely P53, are almost exclusively detected in less differentiated and undifferentiated thyroid tumours, supporting a diagnosis of PDTC or, much more often, UTC. Thyroid-specific rearrangements RET/PTC and PAX8/PPARγ, on the other hand, are rarely found in PDTC and UTC, suggesting that these genetic alterations do not predispose cells to dedifferentiation. In the present review we have summarized the molecular changes associated with the two most aggressive types of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.